表紙
市場調查報告書
商品編碼
1057836

至2026年預測敗血症診斷全球市場:按技術(微生物/PCR/測序/生物標誌物),按產品(試劑/測定/儀器/軟件),按測試類型(實驗室/PoC),按病原體,按最終用戶分類

Sepsis Diagnostics Market by Technology (Microbiology, PCR, Sequencing, Biomarkers), Product(Reagents, Assay, Instruments, Software), Test Type (Lab, POC), Pathogen(Bacterial, Viral, Fungal), End User (Hospital, Pathology Lab) - Global Forecast -2026

出版日期: | 出版商: MarketsandMarkets | 英文 229 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球膿毒症診斷市場將從2021年的5.03億美元增長到2026年的7.17億美元,預計複合年增長率為8.9%。

由於膿毒症發病率增加、外科手術數量增加、醫院感染髮生率增加以及各種膿毒症診斷設備的可用性增加,預計需求將增長。

本報告對全球膿毒症診斷市場進行研究和分析,並提供有關市場概況、行業趨勢、細分市場分析、競爭狀況、主要公司等方面的系統信息。

目錄

第一章介紹

第二章調查方法

第 3 章執行摘要

第 4 章重要考慮

第 5 章市場概述

  • 市場動態
    • 促進因素
    • 抑製器
    • 機會
    • 挑戰
  • 監管情況
  • 專利分析
  • COVID-19 對膿毒症診斷市場的影響
  • 價值鏈分析
  • 價格趨勢分析
  • 兌換場景
  • 波特五力分析
  • 生態系統範圍

第 6 章膿毒症診斷市場:通過技術

  • 血培養(微生物檢測)
  • 免疫分析
  • 分子診斷
  • 流式細胞儀
  • 微流體
  • 生物標誌物

第 7 章膿毒症診斷市場:按產品分類

  • 血液培養基
  • 檢測/試劑盒
  • 設備
  • 軟件

第 8 章膿毒症診斷市場:按方法

  • 常規診斷
  • 自動診斷

第 9 章膿毒症診斷市場:按病原體類型

  • 細菌性敗血症
  • 真菌性敗血症
  • 病毒性敗血症
  • 其他

第 10 章膿毒症診斷市場:按測試類型

  • 實驗室檢查
  • PoC檢查

第 11 章膿毒症診斷市場:按最終用戶

  • 醫院/專科診所
  • 病理學/參考實驗室
  • 研究機構/學術機構

第 12 章膿毒症診斷市場:按地區劃分

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中東/非洲

第13章競爭態勢

  • 概覽
  • 大公司的戰略
  • 頂級市場公司的收入份額分析
  • 市場份額分析
  • 競爭領導力圖譜
  • 初創企業/中小企業的競爭領導力圖譜
  • 膿毒症診斷市場頂級公司的足跡分析
  • 衝突場景

第 14 章公司簡介

  • BIOMERIEUX
  • BECTON, DICKINSON, AND COMPANY
  • DANAHER CORPORATION
  • T2 BIOSYSTEMS
  • LUMINEX
  • F. HOFFMANN-LA ROCHE AG
  • THERMO FISHER SCIENTIFIC
  • BRUKER CORPORATION
  • ABBOTT LABORATORIES
  • QUIDEL CORPORATION
  • SIEMENS HEALTHINEERS
  • EKF DIAGNOSTICS
  • SYSMEX CORPORATION
  • SEEGENE, INC.
  • RESPONSE BIOMEDICAL CORP.
  • 其他企業
    • ALIFAX S.R.L.
    • BODITECH MED INC.
    • ADVANDX
    • IMMUNEXPRESS INC.
    • AXIS-SHIELD DIAGNOSTICS

第15章 附錄

目錄
Product Code: MD 4575

The global sepsis diagnostics market size is expected to reach USD 771 million by 2026 from USD 503 million in 2021, at a CAGR of 8.9%. The demand is expected to grow due to the rising incidence of sepsis, a growing number of surgical procedures, high incidence of hospital-acquired infections, and increasing availability of a wide variety of sepsis diagnostic devices. The sepsis diagnostics industry is segmented on the technology, product, method, pathogen, test type, end user, and region.

"The blood culture segment accounted for the largest share of the sepsis diagnostics industry, by end-user, in 2021."

Based on end-users, the sepsis diagnostics market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. The blood culture accounted for the largest share of the market due to the increasing incidences of sepsis coupled with the growing adoption of blood culture techniques for the diagnosis of sepsis.

"The blood culture media segment accounted for the largest share of the sepsis diagnostics market, by product, in 2021."

The market, by product, is segmented into blood culture media, assays & reagents, instruments, and software. The blood culture media segment accounted for the largest share of the sepsis diagnostics industry due to the usage of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis across the globe.

"North America accounted for the largest share of the sepsis diagnostics market."

North America accounted for the largest share of the global market, followed by Europe. This can primarily be attributed to the extensive availability of advanced sepsis diagnostic technologies, well-established distribution channels, and significant public awareness about the clinical benefits of diagnostic products in risk assessment for infectious diseases.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1: 25%, Tier 2: 30%, and Tier 3: 45%
  • By Designation: C-level: 26%, D-level: 30%, and Others: 44%
  • By Region: North America: 40%, Europe: 31%, APAC: 20%, Latin America: 6%, and the Middle East & Africa: 3%

Some of the prominent players in the sepsis diagnostics market are bioMerieux (France), Becton, Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), Luminex (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), Immunexpress (Australia), Axis-Shield Diagnostics (UK), Quidel Corporation (US), Siemens Healthineers (Germany), EKF Diagnostics (UK), Seegene Inc., (South Korea), Boditech Med (South Korea), Alifax S.r.l. (Italy), AdvanDx (US), (US), Immunexpress (Australia), and Axis-Shield Diagnostics (UK)

Research Coverage

This report studies the sepsis diagnostics market based on technology, product, method, pathogen, test type, end-user, and region. It studies significant factors (such as drivers and restraints) affecting the market growth. The report also analyzes opportunities and challenges in the market for stakeholders. It provides details of the competitive landscape for market leaders with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape users emerging segments of the sepsis diagnostics market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY USED FOR THE STUDY
  • 1.5 MAJOR MARKET STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA SOURCES
      • 2.1.1.1 Indicative list of secondary sources
    • 2.1.2 PRIMARY DATA SOURCES
    • FIGURE 2 BREAKDOWN OF PRIMARIES: SEPSIS DIAGNOSTICS MARKET
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
      • 2.2.1.1 Procedure-based market estimation
    • FIGURE 4 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON PROCEDURE METHODOLOGY
    • FIGURE 5 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON REVENUE MAPPING METHODOLOGY
    • 2.2.2 PRIMARY RESEARCH VALIDATION
  • 2.3 DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    • FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2021 VS. 2026 (USD MILLION)
    • FIGURE 10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 14 THE RISING INCIDENCE OF SEPSIS AND THE RISING NUMBER OF HOSPITAL-ACQUIRED INFECTIONS ARE KEY FACTORS DRIVING THE MARKET GROWTH
  • 4.2 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 15 MOLECULAR DIAGNOSTICS TO REGISTER THE HIGHEST GROWTH IN THE SEPSIS DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • 4.3 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2021 VS. 2026 (USD MILLION)
    • FIGURE 16 CONVENTIONAL DIAGNOSTICS IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET, BY METHOD, DURING THE FORECAST PERIOD
  • 4.4 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY (2021)
    • FIGURE 17 BLOOD CULTURE MEDIA SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET FOR APAC
  • 4.5 GEOGRAPHIC SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET
    • FIGURE 18 APAC MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2021-2026)

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 High incidence of sepsis
      • 5.2.1.2 Rising incidence of hospital-acquired infections
      • 5.2.1.3 Growing funding for sepsis-related research
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of automated diagnostic devices
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis
      • 5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis
      • 5.2.3.3 Growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of awareness and limited protocols for sepsis diagnosis
      • 5.2.4.2 Shortage of skilled healthcare professionals
  • 5.3 REGULATORY LANDSCAPE
    • 5.3.1 NORTH AMERICA
      • 5.3.1.1 US
      • 5.3.1.2 Canada
    • 5.3.2 EUROPE
    • 5.3.3 ASIA PACIFIC
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
    • 5.3.4 LATIN AMERICA
  • 5.4 PATENT ANALYSIS
    • FIGURE 20 TOP 10 PATENT APPLICANTS FOR SEPSIS DIAGNOSTICS (JANUARY 2011 TO DECEMBER 2021)
    • FIGURE 21 NUMBER OF GRANTED PATENT AND PATENT APPLICATIONS FILED BY APPLICATIONS (JANUARY 2011 TO DECEMBER 2021)
    • FIGURE 22 PATENT DOCUMENTS FOR SEPSIS DIAGNOSTICS, BY LEGAL STATUS (JANUARY 2011 TO DECEMBER 2021)
    • FIGURE 23 REGIONAL ANALYSIS OF PATENTS GRANTED FOR SEPSIS DIAGNOSTICS (JANUARY 2011 TO DECEMBER 2021)
  • 5.5 COVID-19 IMPACT ON THE SEPSIS DIAGNOSTICS MARKET
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 24 VALUE CHAIN OF THE SEPSIS DIAGNOSTICS MARKET
  • 5.7 PRICING TREND ANALYSIS
    • TABLE 1 AVERAGE PRICE OF SEPSIS DIAGNOSTICS BLOOD CULTURE MEDIA, ASSAYS & REAGENT KITS AND EQUIPMENT, BY COUNTRY, 2020 (USD)
  • 5.8 REIMBURSEMENT SCENARIO
    • TABLE 2 MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 3 SEPSIS DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • FIGURE 25 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • FIGURE 26 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF SUPPLIERS
    • FIGURE 27 BARGAINING POWER OF SUPPLIERS
    • 5.9.4 BARGAINING POWER OF BUYERS
    • FIGURE 28 BARGAINING POWER OF BUYERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
    • FIGURE 29 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 ECOSYSTEM COVERAGE

6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 4 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
  • 6.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
    • 6.2.1 BLOOD CULTURE IS THE MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS
    • TABLE 5 BLOOD CULTURE MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 6 BLOOD CULTURE MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 7 BLOOD CULTURE MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 8 BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 9 BLOOD CULTURE MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 10 BLOOD CULTURE MARKET, BY END USER, 2019-2026(USD MILLION)
  • 6.3 IMMUNOASSAYS
    • 6.3.1 PRODUCT DEVELOPMENT BY MAJOR PLAYERS HAS ENSURED THE DEMAND FOR IMMUNOASSAYS
    • TABLE 11 IMMUNOASSAYS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 12 IMMUNOASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 13 IMMUNOASSAYS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 14 IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 15 IMMUNOASSAYS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 16 IMMUNOASSAYS DIAGNOSTICS MARKET, BY END USER, 2019-2026(USD MILLION)
  • 6.4 MOLECULAR DIAGNOSTICS
    • TABLE 17 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026(USD MILLION)
    • TABLE 18 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 19 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 21 MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 22 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2026(USD MILLION)
    • 6.4.1 POLYMERASE CHAIN REACTION (PCR)
      • 6.4.1.1 Quick turnaround time, coupled with technological advancements to increase the adoption of PCR for sepsis diagnosis
    • TABLE 24 PCR MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 25 PCR MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 26 PCR MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 27 PCR MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 28 PCR MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 29 PCR MARKET, BY END USER, 2019-2026(USD MILLION)
    • 6.4.2 DNA MICROARRAYS
      • 6.4.2.1 Simultaneous analysis capabilities & accuracy have driven the use of microarrays
    • TABLE 30 DNA MICROARRAYS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 31 DNA MICROARRAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 32 DNA MICROARRAYS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 33 DNA MICROARRAYS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 34 DNA MICROARRAYS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 35 DNA MICROARRAYS MARKET, BY END USER, 2019-2026(USD MILLION)
    • 6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION (PNA-FISH)
      • 6.4.3.1 PNA-FISH kits allow for the rapid diagnosis of bloodstream infections (BSIs)
    • TABLE 36 PNA-FISH MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 37 PNA-FISH MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 38 PNA-FISH MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 39 PNA-FISH MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 40 PNA-FISH MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 41 PNA-FISH MARKET, BY END USER, 2019-2026(USD MILLION)
    • 6.4.4 DNA SEQUENCING
      • 6.4.4.1 DNA Sequencing shortens the time for sepsis diagnosis, and NGS has applications in COVID-19 diagnosis
    • TABLE 42 DNA SEQUENCING, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 43 DNA SEQUENCING MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 44 DNA SEQUENCING MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 45 DNA SEQUENCING MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 46 DNA SEQUENCING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 47 DNA SEQUENCING MARKET, BY END USER, 2019-2026(USD MILLION)
    • 6.4.5 SYNDROMIC PANEL-BASED TESTING
      • 6.4.5.1 High costs and accuracy errors limit the adoption of syndromic-panel-based tests
    • TABLE 48 SYNDROMIC PANEL-BASED TESTING MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 49 SYNDROMIC PANEL-BASED TESTING MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 50 SYNDROMIC PANEL-BASED TESTING MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 51 SYNDROMIC PANEL-BASED TESTING MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 52 SYNDROMIC PANEL-BASED TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 53 SYNDROMIC PANEL-BASED TESTING MARKET, BY END USER, 2019-2026(USD MILLION)
  • 6.5 FLOW CYTOMETRY
    • 6.5.1 LACK OF STANDARDIZED PROTOCOLS IS A KEY RESTRAINT IN FLOW CYTOMETRY
    • TABLE 54 FLOW CYTOMETRY MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 55 FLOW CYTOMETRY MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 56 FLOW CYTOMETRY MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 57 FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 58 FLOW CYTOMETRY MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 59 FLOW CYTOMETRY MARKET, BY END USER, 2019-2026(USD MILLION)
  • 6.6 MICROFLUIDICS
    • 6.6.1 RISING ADOPTION OF ADVANCED & RAPID TESTING TO DRIVE THE GROWTH OF THE MICROFLUIDICS SEGMENT
    • TABLE 60 MICROFLUIDICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 61 MICROFLUIDICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 62 MICROFLUIDICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 63 MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 64 MICROFLUIDICS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 65 MICROFLUIDICS MARKET, BY END USER, 2019-2026(USD MILLION)
  • 6.7 BIOMARKERS
    • 6.7.1 RESEARCH & DEVELOPMENT FOR THE DISCOVERY OF NOVEL BIOMARKERS TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 66 BIOMARKERS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 67 BIOMARKERS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 68 BIOMARKERS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 69 BIOMARKERS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 70 BIOMARKERS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 71 BIOMARKERS MARKET, BY END USER, 2019-2026(USD MILLION)

7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT

  • 7.1 INTRODUCTION
    • TABLE 72 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
  • 7.2 BLOOD CULTURE MEDIA
    • 7.2.1 RISE IN BLOODSTREAM INFECTIONS TO DRIVE THE GROWTH OF BLOOD CULTURE MEDIA IN SEPSIS DIAGNOSIS
    • FIGURE 30 INCIDENCE OF BLOODSTREAM INFECTIONS BY AGE AND SEX, WESTERN INTERIOR OF BRITISH COLUMBIA AND CANADA, 2010-2019
    • TABLE 73 BLOOD CULTURE MEDIA MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.3 ASSAYS & REAGENT KITS
    • 7.3.1 ASSAYS BETTER ENABLE THE ANALYSIS OF PATIENT SAMPLES FOR DISEASE DIAGNOSIS
    • TABLE 74 ASSAYS & REAGENT KITS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.4 INSTRUMENTS
    • 7.4.1 TRADITIONAL DIAGNOSTIC INSTRUMENTS ARE GRADUALLY BEING REPLACED BY AUTOMATED INSTRUMENTS
    • TABLE 75 INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 7.5 SOFTWARE
    • 7.5.1 RISING USE OF AUTOMATED INSTRUMENTS TO ENSURE THE GROWING DEMAND FOR SOFTWARE
    • TABLE 76 SOFTWARE MARKET, BY REGION, 2019-2026 (USD MILLION)

8 SEPSIS DIAGNOSTICS MARKET, BY METHOD

  • 8.1 INTRODUCTION
    • TABLE 77 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • 8.1.1 CONVENTIONAL DIAGNOSTICS
      • 8.1.1.1 Higher adoption of conventional diagnostics owing to blood culture testing to drive the growth of this segment
    • TABLE 78 CONVENTIONAL DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • 8.1.2 AUTOMATED DIAGNOSTICS
      • 8.1.2.1 Accuracy & quick turnaround times to drive the adoption of automated diagnostics among medical professionals
    • TABLE 79 AUTOMATED DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)

9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE

  • 9.1 INTRODUCTION
    • TABLE 80 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
  • 9.2 BACTERIAL SEPSIS
    • TABLE 81 BACTERIAL SEPSIS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
      • 9.2.1.1 Increased proportion of sepsis infection caused by gram-negative bacteria
    • TABLE 82 GRAM-NEGATIVE BACTERIAL CAUSES IN ADULT SEPSIS
    • TABLE 83 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • 9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
      • 9.2.2.1 Cases of sepsis caused by gram-positive bacteria have risen in recent years
    • TABLE 84 GRAM-POSITIVE BACTERIAL CAUSES IN ADULT SEPSIS
    • TABLE 85 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 9.3 FUNGAL SEPSIS
    • 9.3.1 THE RISING INCIDENCE OF FUNGAL HAIS HAS INCREASED THE RISK OF SEPSIS DEVELOPMENT
    • TABLE 86 FUNGAL SEPSIS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 9.4 VIRAL SEPSIS
    • 9.4.1 VIRAL PATHOGEN A NEW CAUSATIVE AGENT OF SEPSIS
    • TABLE 87 VIRAL SEPSIS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 9.5 OTHER PATHOGENS
    • TABLE 88 OTHER PATHOGENS MARKET, BY REGION, 2019-2026 (USD MILLION)

10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE

  • 10.1 INTRODUCTION
    • TABLE 89 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
  • 10.2 LABORATORY TESTS
    • 10.2.1 LABORATORY TESTS ARE THE MOST COMMON AND PREFERRED MODE OF TESTING
    • TABLE 90 LABORATORY TEST MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 2019-2026(USD MILLION)
  • 10.3 POINT-OF-CARE TESTS
    • 10.3.1 RAPID POC TESTING DRIVES THE GROWTH OF THIS SEGMENT
    • TABLE 91 POC TESTS MARKET FOR SEPSIS DIAGNOSTICS, NY REGION, 2019-2026(USD MILLION)

11 SEPSIS DIAGNOSTICS MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 92 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019-2026(USD MILLION)
  • 11.2 HOSPITALS AND SPECIALTY CLINICS
    • 11.2.1 INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO BOOST SEGMENT GROWTH
    • TABLE 93 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS AND SPECILAITY CLINICS, BY REGION, 2019-2026 (USD MILLION)
  • 11.3 PATHOLOGY & REFERENCE LABORATORIES
    • 11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES
    • TABLE 94 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2019-2026 (USD MILLION)
  • 11.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
    • 11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION DRIVES THE GROWTH OF THIS SEGMENT
    • TABLE 95 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2019-2026 (USD MILLION)

12 SEPSIS DIAGNOSTICS MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • FIGURE 31 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 96 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 97 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 98 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 99 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 100 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 101 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 102 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019-2026(USD MILLION)
    • 12.2.1 US
      • 12.2.1.1 Rising incidence of HIAS in us to accelerate the demand for sepsis diagnosis
    • TABLE 103 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 104 US: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.2.2 CANADA
      • 12.2.2.1 The growing availability of sepsis diagnostic products is expected to drive market growth in Canada
    • TABLE 105 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 106 CANADA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
  • 12.3 EUROPE
    • TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 108 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 109 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 110 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 111 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 112 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 113 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019-2026(USD MILLION)
    • 12.3.1 GERMANY
      • 12.3.1.1 Growing awareness and the adoption of technologically advanced diagnostics products in Germany to drive the market growth
    • TABLE 114 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 115 GERMANY: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.3.2 UK
      • 12.3.2.1 Government support and rising awareness for the early diagnosis of sepsis are the key factors driving market growth in the UK
    • TABLE 116 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 117 UK: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.3.3 FRANCE
      • 12.3.3.1 The high incidence of sepsis in France has supported the demand for sepsis diagnostic products
    • TABLE 118 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 119 FRANCE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.3.4 ITALY
      • 12.3.4.1 Limited growth in the healthcare sector to restrain the market growth for sepsis diagnostics in Italy
    • TABLE 120 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 121 ITALY: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.3.5 SPAIN
      • 12.3.5.1 Rising awareness for the early diagnosis of sepsis to drive the market growth in Spain
    • TABLE 122 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 123 SPAIN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.3.6 REST OF EUROPE
    • TABLE 124 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 125 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
  • 12.4 ASIA PACIFIC
    • TABLE 126 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 127 ASIA PACIFIC: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 128 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 129 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 130 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 131 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019-2026(USD MILLION)
    • 12.4.1 JAPAN
      • 12.4.1.1 Rising incidence of pneumonia and infectious diseases to support the market growth in Japan
    • TABLE 133 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 134 JAPAN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.4.2 CHINA
      • 12.4.2.1 Healthcare infrastructure improvements to support the market growth for sepsis diagnostics in China
    • TABLE 135 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 136 CHINA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.4.3 INDIA
      • 12.4.3.1 Increasing patient population and the rising number of surgical procedures to drive the market growth in India
    • TABLE 137 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 138 INDIA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.4.4 AUSTRALIA
      • 12.4.4.1 The increasing number of sepsis treatment procedures indicates growth potential for the sepsis diagnostics market in Australia
    • TABLE 139 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 140 AUSTRALIA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Rising healthcare spending to support the market growth in South Korea
    • TABLE 141 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 142 SOUTH KOREA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.4.6 THE REST OF ASIA PACIFIC (ROAPAC)
    • TABLE 143 ROAPAC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 144 ROAPAC: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
  • 12.5 LATIN AMERICA
    • TABLE 145 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 146 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 147 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 148 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 149 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 150 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 151 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019-2026(USD MILLION)
    • 12.5.1 BRAZIL
      • 12.5.1.1 Brazil accounted for the largest share of the LATAM market in 2020 owing to the ongoing investments by manufacturers in the country
    • TABLE 152 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 153 BRAZIL: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.5.2 MEXICO
      • 12.5.2.1 Rising medical tourism to support the market growth in Mexico
    • TABLE 154 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 155 MEXICO: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • 12.5.3 THE REST OF LATIN AMERICA (ROLATAM)
    • TABLE 156 ROLATAM: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 157 ROLATAM: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS DRIVES SEPSIS OCCURRENCE IN THE MEA REGION
    • TABLE 158 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 159 MIDDLE EAST & AFRICA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 160 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 161 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
    • TABLE 162 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019-2026 (USD MILLION)
    • TABLE 163 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 164 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019-2026(USD MILLION)

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 KEY PLAYER STRATEGIES
  • 13.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
  • 13.4 MARKET SHARE ANALYSIS (2020)
    • TABLE 165 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • 13.5 COMPETITIVE LEADERSHIP MAPPING
    • 13.5.1 STARS
    • 13.5.2 PERVASIVE PLAYERS
    • 13.5.3 EMERGING LEADERS
    • 13.5.4 PARTICIPANTS
    • FIGURE 33 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
  • 13.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020)
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 STARTING BLOCKS
    • 13.6.3 RESPONSIVE COMPANIES
    • 13.6.4 DYNAMIC COMPANIES
    • FIGURE 34 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2020
  • 13.7 FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE SEPSIS DIAGNOSTICS MARKET
    • TABLE 166 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE SEPSIS DIAGNOSTICS MARKET
    • TABLE 167 PRODUCT FOOTPRINT OF COMPANIES
    • TABLE 168 REGIONAL FOOTPRINT OF COMPANIES
  • 13.8 COMPETITIVE SCENARIO
    • 13.8.1 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS
    • TABLE 169 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS, JANUARY 2018-DECEMBER 2021
    • 13.8.2 SEPSIS DIAGNOSTICS MARKET: DEALS
    • TABLE 170 KEY DEALS, JANUARY 2018-DECEMBER 2021
    • 13.8.3 SEPSIS DIAGNOSTICS MARKET: OTHER DEVELOPMENTS
    • TABLE 171 OTHER KEY DEVELOPMENTS, JANUARY 2018-DECEMBER 2021

14 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
  • 14.1 BIOMERIEUX
    • TABLE 172 BIOMERIEUX.: BUSINESS OVERVIEW
    • FIGURE 35 BIOMERIEUX: COMPANY SNAPSHOT (2020)
    • TABLE 173 BIOMERIEUX.: PRODUCT OFFERINGS
  • 14.2 BECTON, DICKINSON, AND COMPANY
    • TABLE 174 BECTON, DICKINSON, AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 36 BECTON, DICKINSON, AND COMPANY: COMPANY SNAPSHOT (2020)
    • TABLE 175 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS
  • 14.3 DANAHER CORPORATION
    • TABLE 176 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
    • TABLE 177 DANAHER CORPORATION: PRODUCT OFFERINGS
  • 14.4 T2 BIOSYSTEMS
    • TABLE 178 T2 BIOSYSTEMS: BUSINESS OVERVIEW
    • FIGURE 38 T2 BIOSYSTEMS: COMPANY SNAPSHOT (2020)
    • TABLE 179 T2 BIOSYSTEMS: PRODUCT OFFERINGS
  • 14.5 LUMINEX
    • TABLE 180 LUMINEX: BUSINESS OVERVIEW
    • FIGURE 39 LUMINEX: COMPANY SNAPSHOT (2020)
    • TABLE 181 LUMINEX: PRODUCT OFFERINGS
  • 14.6 F. HOFFMANN-LA ROCHE AG
    • TABLE 182 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
    • FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
    • TABLE 183 F. HOFFMANN-LA ROCHE AG: PRODUCT OFFERINGS
  • 14.7 THERMO FISHER SCIENTIFIC
    • TABLE 184 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 41 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
    • TABLE 185 THERMO FISHER SCIENTIFIC: PRODUCT OFFERINGS
  • 14.8 BRUKER CORPORATION
    • TABLE 186 BRUKER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 42 BRUKER CORPORATION: COMPANY SNAPSHOT (2020)
    • TABLE 187 BRUKER CORPORATION: PRODUCT OFFERINGS
  • 14.9 ABBOTT LABORATORIES
    • TABLE 188 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
    • TABLE 189 ABBOTT LABORATORIES: PRODUCT OFFERINGS
  • 14.10 QUIDEL CORPORATION
    • TABLE 190 QUIDEL CORPORATION: BUSINESS OVERVIEW
    • FIGURE 44 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
    • TABLE 191 QUIDEL CORPORATION: PRODUCT OFFERINGS
  • 14.11 SIEMENS HEALTHINEERS
    • TABLE 192 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
    • FIGURE 45 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
    • TABLE 193 SIEMENS HEALTHINEERS: PRODUCT OFFERINGS
  • 14.12 EKF DIAGNOSTICS
    • TABLE 194 EKF DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 46 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2020)
    • TABLE 195 EKF DIAGNOSTICS: PRODUCT OFFERINGS
  • 14.13 SYSMEX CORPORATION
    • TABLE 196 SYSMEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 47 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
    • TABLE 197 SYSMEX CORPORATION: PRODUCT OFFERINGS
  • 14.14 SEEGENE, INC.
    • TABLE 198 SEEGENE, INC.: BUSINESS OVERVIEW
    • TABLE 199 SEEGENE, INC: PRODUCT OFFERINGS
  • 14.15 RESPONSE BIOMEDICAL CORP.
    • TABLE 200 RESPONSE BIOMEDICAL CORP.: BUSINESS OVERVIEW
    • TABLE 201 RESPONSE BIOMEDICAL CORP.: PRODUCT OFFERINGS
  • 14.16 OTHER COMPANIES
    • 14.16.1 ALIFAX S.R.L.
    • 14.16.2 BODITECH MED INC.
    • 14.16.3 ADVANDX
    • 14.16.4 IMMUNEXPRESS INC.
    • 14.16.5 AXIS-SHIELD DIAGNOSTICS
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 AVAILABLE CUSTOMIZATIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS